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SObjective:Uncertainty exists among surgeons as towhetherminimally invasive esophagectomy (MIE) is a com-
parable operation to open esophagectomy (OE). The surgical technique and oncologic dissection should not be
degraded when using a minimally invasive approach.
Methods:We reviewed a single hospital’s experience with both OE and MIE. From 2000 to 2010, 257 patients
underwent esophagectomy by 1 of 3 surgical techniques: transhiatal, Ivor Lewis, or 3-hole.
Results: Of the 257 patients (median age, 67 years; range, 58–74), 92 underwent MIE. Both groups were com-
parable in terms of gender, age, comorbidities, surgical technique, and induction chemotherapy and radiother-
apy. The overall median follow-up was 29.5 months (range, 9.9–61.5). TheMIE group had a significantly shorter
operative time (MIE vs OE, 330 vs 365 minutes, P ¼ .04), length of stay (MIE vs OE, 9 vs 12 days, P<.01),
intensive care unit admission rate (MIE vs OE, 55% vs 81%, P<.01), intensive care unit length of stay (MIE vs
OE, 1 vs 2 days, P<.01), and estimated blood loss (MIE vs OE, 100 vs 400 mL, P<.01). More lymph nodes
were harvested in the MIE group than in the OE group (17 vs 11 nodes, P<.01). There were insignificant dif-
ferences in 30-day mortality (MIE vs OE, 2.2% vs 3.0%; P ¼ .93) and overall survival (P ¼ .19), as well as in
the rates of all complications, except pneumonia (MIE vs OE, 2% vs 13%; P ¼ .01).
Conclusions: A thoracic surgeon can safely tailor the MIE to a patient’s anatomy and oncologic demands while
maintaining equivalent survival. (J Thorac Cardiovasc Surg 2012;143:1125-9)The surgical treatment of esophageal cancer involves esoph-
agectomywith en bloc nodal dissection and reconstitution of
the alimentary track. There are 3 standard techniques for
performing an open esophagectomy (OE): the transhiatal
esophagectomy (THE), transthoracic or Ivor Lewis (IL)
esophagectomy, and McKeown’s 3-phase or 3-hole (3H)
technique.1-3 In the years since, both prospective and
retrospective studies have found no statistically significant
advantage for 1 technique over another, as it pertains to
OE.4-6 Each technique has its risks and benefits.7 Accord-
ingly, the characteristics and location of the esophageal
tumor, along with the patient’s global health, can contribute
to determining which procedure is performed.4
The traditional OE entails significant morbidity.5 The
need to reduce this morbidity has led to the development
of minimally invasive techniques for performing each of
the 3 types of esophagectomy.8,9 Owing to the technicallye Divisions of Cardiothoracic Surgerya and Minimally Invasive Surgery,b Co-
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The Journal of Thoracic and Cardemanding nature of this procedure, access to minimally
invasive esophagectomy (MIE) has been limited to
select specialized centers that have been able to show
comparable results. However, such high-volume centers
tend to advocate a specific minimally invasive technique,
such as Ivor Lewis or transhiatal esophagectomy, reflecting
the learning curve and experience of each institution. For
the MIE to be truly equivalent in the treatment of esopha-
geal cancer to OE, patients would need to be offered the
technique best suited to them and their disease.
The outcomes of patients with esophageal carcinoma
who were treated with a tailored OE were compared with
those of patients treated with a tailored MIE. We examined
whether a difference between the outcomes in these 2 co-
horts existed. A unique aspect of our study population
was that disease characteristics dictated which minimally
invasive technique they were offered.
METHODS
The present study, which was approved by the Columbia University
Medical Center institutional review board, was a retrospective review of
a single institution’s experience with both OE and MIE.
Patient Selection
From February 2000 to June 2010, 257 consecutive patients underwent
esophagectomy for a preoperative diagnosis of cancer using 1 of 3 surgical
techniques: THE, IL, or 3H.
Descriptive statistics were collected. A thorough review of the inpatient
and outpatient clinical records was conducted to ascertain informationdiovascular Surgery c Volume 143, Number 5 1125
Abbreviations and Acronyms
3H ¼ 3-hole
MIE ¼ minimally invasive esophagectomy
OE ¼ open esophagectomy
THE ¼ transhiatal esophagectomy
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Sregarding the patient’s operative course, postoperative hospitalization, pos-
sible intensive care unit (ICU) stay, and pathology reports. Staging was de-
termined using the American Joint Committee on Cancer Staging Manual,
7th edition.10 The short- and long-term follow-up data, including compli-
cation rates or adverse events, were also documented. Postoperative pneu-
monia was defined by a new infiltrate on chest x-ray plus 2 of the following:
leukocytosis, hypoxia, fever, or positive sputum culture.11 Owing to the
limited availability of the retrospective data, the ‘‘operative time’’ was de-
fined as the interval fromwhen the patient was anesthesia ready towhen the
patient left the operating room. The patients were followed up routinely by
their primary surgeon and by the gastroenterologists and oncologists within
the same healthcare system.
The demographic characteristics of the study population were recorded
(Table 1). A total of 7 surgeons performed the open and minimally invasive
procedures.
Surgery
The open procedures were conducted in standard fashion, specific to
each technique.12 The minimally invasive procedures were completed
using slight modifications of the described techniques for minimally
invasive IL esophagectomy, THE, and 3H esophagectomy.4,13-15 All
esophagectomies received a feeding jejunosotomy tube. To facilitate
gastric emptying, the open procedures included pyloroplasty. The
minimally invasive procedures initially also included pyloroplasty that
was later transitioned to endoscopically injected botulinum toxin into the
pylorus combined with dilation. To expedite work in the foregut, the
MIE was performed on a bariatric surgery table that could tilt 45, and
long laparoscopic and thoracoscopic instruments were used. A high-
definition camera and monitors allowed for improved visualization, and
a video mediastinoscope facilitated cervical neck dissection.
Hybrid procedures, such as laparoscopic gastric mobilization followed
by thoracotomy or laparotomy with thoracoscopic mobilization, were not
included in the analysis. A distinction was made between hybrid proce-
dures (n ¼ 8) and conversion to OE (n ¼ 3). In the latter, a procedure
that was intended to be performed entirely by a minimally invasive ap-
proach required open completion.
The lymphadenectomy performed was standard and included upper and
lower mediastinal paraesophageal, pericardial, celiac trunk, lesser curva-
ture of the stomach, left gastric artery, splenic artery, and carinal nodal ba-
sins.16 In general, induction therapy was offered to patients who had T3 or
N1 disease by endoscopic ultrasonography and who were also thought to
have performance status to support trimodality therapy. The chemotherapy
given was a mix of differing regimens, as the referring oncologists most of-
ten provided the therapy. Most were cisplatin-based regimens. Radiation
was standard dosing to 50.5 Gy, as tolerated.
Statistical Analysis
All statistical analyses were performed with a statistical software pack-
age (StataCorp, College Station, Tex). Thevalues are reported as themedian
and interquartile range. To minimize potential concerns regarding the nor-
mality of the data distribution, nonparametric rank sum tests were used to
compare the continuous variables, as appropriate. Categorical variables
were compared using chi-square tests. The mortality data were confirmed
using the Social Security Death Index. The follow-up time was defined as
the postoperative time to the last office visit. Survival comparisons were1126 The Journal of Thoracic and Cardiovascular Surmade with Kaplan-Meier analysis, with survival estimates compared
using a log-rank test. Overall survival was defined as the time from the
date of surgery to death or the last follow-up visit through July 15, 2011.RESULTS
From February 2000 to June 2010, 257 patients under-
went esophagectomy at our institution. During this period,
92 MIEs were performed. Of the 257 patients, 194 were
men (75%), and themedian patient agewas 67 years (range,
58–74). The OE and MIE cohorts were equally matched in
terms of gender, age, and instances of induction chemother-
apy and radiation (Table 1). The 3 surgical techniques (THE,
IL, 3H) were distributed similarly between the OE and MIE
(P ¼ .27). A significant difference was found in the patho-
logic tumor stage between the 2 groups (P ¼ .01). This
was attributed to more stage III disease in the OE cohort
(42% vs 29% in the MIE cohort; Table 1). All the patients
with stage 0 disease on the final pathologic examination
(10 MIE patients and 4 OE patients) had preoperative clin-
ical stage I (6 MIE and 2 OE), II (2 MIE and 1 OE), and
III (2MIE and 1OE) according to the endoscopic ultrasound
findings. The patients with stage II and III disease under-
went combined induction chemoradiotherapy and were
believed to have achieved a complete pathologic response.
The overall median follow up was 29.5 months (range,
9.9–61.5). The median follow-up for the OE group was lon-
ger (52 months; range, 13–83) than that for the MIE group
(21 months; range, 11–37). The final surgical pathologic ex-
amination revealed that 91% of the MIE group had adeno-
carcinoma compared with 84% of the OE group (P ¼ .14).
R0 or complete pathologic resection was accomplished in
99% of the MIE cohort compared with 94% of the OE
group (P ¼ .10). The lone MIE patient had radial margins
involved and postoperatively was found to have stage IIIc
disease on final pathologic examination. All the patients
without R0 resection in the OE group had positive radial
margins on final pathologic examination. The cohort that re-
ceived induction chemotherapy and radiotherapy repre-
sented 55% (n ¼ 51) of the MIE patients and 58%
(n ¼ 96) of the OE patients (P ¼ .29).
When comparing the MIE and OE group, the MIE cohort
had a significantly shorter operative time, length of stay,
ICU admission rate, ICU length of stay, and estimated blood
loss (Table 2). Significantly more lymph nodes were har-
vested in the MIE group (Table 2). Subgroup analysis dem-
onstrated significantly improved nodal dissection among the
MIE performed using the IL and THE techniques and an in-
significant trend favoringMIE among the 3H subgroup. The
median number of lymph nodes harvested per final patho-
logic stage was greater for the MIE approach (P<.01).
With the exception of postoperative pneumonia, there
was not a significant difference between the rates of adverse
events, including anastomotic or chyle leak requiring reop-
eration, strictures needing dilation, recurrent laryngealgery c May 2012
TABLE 1. Baseline characteristics
Characteristic MIE OE P value
Sample size (n) 92 (36) 165 (64)
Age (y) .74
Mean 65 68
Range 56–74 60–74
Men (n) 71 (77) 122 (74) .99
Adenocarcinoma 84 (91) 139 (84) .14
Squamous cell carcinoma 8 (9) 26 (16) .14
R0 resection 91 (99) 155 (94) .10
Esophagectomy technique .81
Transhiatal 49 (53.3) 81 (49)
Ivor Lewis 27 (29.3) 53 (32)
3-Hole 16 (17.3) 31 (19)
Pathologic tumor stage .01
0 10 (11) 4 (2)
I 36 (39) 65 (40)
II 19 (21) 27 (16)
III 27 (29) 69 (42)
Surgical technique .29
Transhiatal 27 (53) 47 (49)
Ivor Lewis 15 (29) 31 (32)
3-Hole 9 (18) 18 (19)
Preoperative comorbidity
Hypertension 45 (49) 84 (51) .68
Diabetes 22 (24) 35 (21) .53
Hyperlipidemia 26 (28) 31 (19) .11
Chronic obstructive pulmonary
disease
9 (10) 23 (14) .26
Asthma 9 (10) 12 (7) .46
Coronary artery disease 9 (9) 23 (14) .26
Data presented as mean and range or n (%). MIE, Minimally invasive esophagec-
tomy; OE, open esophagectomy.
TABLE 2. Results
Variable MIE OE P value
Operative time* (min)
Median 330 365 .04
Interquartile range 288–411 319–472
Length of stay (d) <.01
Median 9 12
Interquartile range 8–14 10–21
ICU admission rate (%) 55 81 <.01
ICU length of stay (d) <.01
Median 1 2
Interquartile range 0–2 1–4
Estimated blood loss (mL) <.01
Median 100 400
Interquartile range 50–300 250–600
Nodes harvested
Overall <.01
Median 17 11
Interquartile range 12.5–24.5 7–16
Transhiatal
Median 17 13 <.01
Interquartile range 14–22.5 5–15
Ivor Lewis
Median 19 12 .03
Interquartile range 13–27 9–19
Three-hole
Median 16 10 .39
Interquartile range 12–23 11–19
Conversion to OE 3 (3) NA NA
Data in parentheses are percentages. MIE, Minimally invasive esophagectomy;
OE, open esophagectomy; ICU, intensive care unit. *From anesthesia ready to out
of the operating room.
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vention (Table 3). The cases of conduit torsion were limited
to the THE and 3H groups. Similarly, the incidence of recur-
rent laryngeal nerve injury was associated with the presence
of cervical incision and anastomosis (THE and 3H), and no
significant difference was found between the MIE and OE
cohorts (P ¼ .21). Among the 3 MIE techniques, the data
suggest that there was in an insignificant difference in the
number of nodes harvested (P¼ .42), the incidence of com-
plications (P ¼ .65), and the survival rates (P ¼ .9).
After stratifying for tumor stage and surgical technique,
there was an insignificant statistical difference in the 30-
day mortality rate (MIE, 2.2% vs OE, 3.0%; P ¼ .93),
in-hospital mortality rate (MIE, 3.2% vs OE, 4.2%;
P ¼ 1.00), and the overall survival rate (P ¼ .19;
Figure 1). Similarly, no significant survival difference was
found between the 2 approaches in the cohort that received
neoadjuvant chemotherapy (P ¼ .25).CONCLUSIONS
The present series reflects a single institution’s initial ex-
perience with transitioning from OE to MIE. It was ourThe Journal of Thoracic and Carintent to offer identical surgical approaches according to
the patient and tumor characteristics. Two similar cohorts
undergoing either OE or MIE were studied and found to
have comparable survival. Using the same surgical decision
making as for OE, a specific MIE technique (THE, IL, or
3H) was tailored to the patient’s needs and was not limited
by institutional preference or experience. This differed from
previous studies in which often only 1 minimally invasive
technique was offered to patients.15,17 Mostly, patients
with early-stage or limited gastroesophageal junction dis-
ease were transhiatal candidates and those with more ad-
vanced and/or bulkier disease underwent either an IL or
3H esophagectomy. This led to a correlation between surgi-
cal technique and pathologic tumor stage.
The present study included the work of 7 surgeons. Ini-
tially, the MIEs were performed by 2 surgeons and the ex-
perience was extended through the group. The number of
surgeons involved counters the single-institution nature of
the study and might make the data more applicable. No
operator-specific preferences were present in the surgical
approach or esophagectomy technique used, instead the
patient, nature of the disease, and the anatomy determined
the approach and technique used. Furthermore, nodiovascular Surgery c Volume 143, Number 5 1127
TABLE 3. Complication rate
Variable
MIE
(n ¼ 92)
OE
(n ¼ 165)
P
value
Recurrent laryngeal nerve
injury
3 (3) 10 (6) .21
Heart failure 2 (2) 2 (1) .52
Stroke 0 (0) 2 (1) .55
Atrial fibrillation 22 (24) 46 (28) .49
Wound infection 19 (21) 33 (20) .90
Delayed gastric emptying* 17 (18) 31 (19) .91
Acute renal failurey 1 (1) 5 (3) .14
Deep venous thrombosis 2 (2) 4 (2) .55
Pulmonary embolism 3 (3) 4 (2) .57
Pulmonary complications 9 (10) 26 (16) .94
Pneumonia 2 (2) 21 (13) .01
Postoperative respiratory
failure
7 (8) 14 (8) .78
Reintubated 5 (5) 10 (6) .75
Tracheotomy 2 (2) 4 (2) .75
Adverse events requiring
intervention
Conduit torsion 2 (2) 2 (1) .25
Anastomotic leak 5 (5) 7 (4) .65
Chylous leak 3 (3) 5 (3) .91
Esophageal stricture 7 (8) 11 (7) .17
Bleeding 3 (3) 2 (1) .25
Data presented as n (%).MIE, Minimally invasive esophagectomy; OE, open esoph-
agectomy. *Diagnosed by upper gastrointestinal series. yDefined by an increase in se-
rum creatinine of 50%.
FIGURE 1. Overall survival for open and minimally invasive
esophagectomy .
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mortality, or overall survival.
Similar to other minimally invasive procedures, the MIE
was associated with a shorter length of stay, ICU admission
rate, ICU length of stay, and lower estimated blood loss.18
The shorter operative times were not substantial and likely
resulted from the advanced experience of the minimally in-
vasive surgeons. In both cohorts, the operative times re-
ported were prolonged owing in part to the limited data.
The skin incision and skin closure times were not available
for all patients. This required that the ‘‘operative time’’ in-
clude preparing, positioning, and moving the patient onto
a stretcher with the appropriate monitoring for transporta-
tion to recovery. The procedures were performed in a teach-
ing institution, which might have also played a factor.
MIE, in particular the transhiatal and transthoracic tech-
niques, were also associated with significantly greater
lymph node recovery. This might be attributable to the im-
proved and magnified visualization that is afforded with the
minimally invasive techniques. However, improved nodal
clearance could also have been significantly affected by sur-
geon intent over time. Presently, there is a significant impe-
tus on the part of both the surgeon and the pathologist to
enhance nodal recovery rates. This, combined with a greater
proportion of MIEs performed recently, might be sufficient
to account for the differences in nodal recovery. When the1128 The Journal of Thoracic and Cardiovascular Survarious techniques within each approach were compared,
insignificant differences were found in the number of nodes
harvested and their ranges overlapped. Therefore, we cau-
tion against concluding anything beyond comparable lymph
node dissection.
In reporting adverse events, a distinction was made be-
tween anastomotic leaks as visualized on barium swallow
testing or requiring a formal revision or washout versus
leaks that contribute to wound infection but could be man-
aged by opening the wound at the bedside. Only a portion of
patients with wound infections had a leak defined by esoph-
agography or that required operative evaluation or treat-
ment. Our group has a very low threshold to open cervical
incisions to rule out potential sources of infection, and these
suspected leaks were included in the reporting of wound in-
fections. As was the case with most other types of adverse
events, no difference was found between the OE and MIE
cohorts.
Consistent with other studies, the MIE group had a lower
rate of postoperative pneumonia.18 The recurrent laryngeal
nerve injury rate is thought to be underreported for all
esophagectomies, because it is not the policy at our institu-
tion for postesophagectomy patients to routinely be exam-
ined by an ear, nose, and throat specialist. Patients are
examined if clinical evidence is present to suggest vocal
cord pathology, such as a failed speech and swallow exam-
ination or persistent hoarseness. Accordingly, instances of
clinically insignificant recurrent laryngeal nerve injury
might not have been detected.
The present study was limited by its retrospective, single-
institution nature. Selection bias was lessened, and the
learning curve with minimally invasive techniques was
taken to account by using consecutive patients for a slightly
more than 10-year span. The large sample size and similar
composition of both cohorts strengthened the comparisons;gery c May 2012
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Showever, it should be noted that the OE cohort had more pa-
tients with stage III disease. Therefore, any definitive con-
clusions regarding comparability might be limited to stage
I and II disease. The subset of patients found to have stage
0 disease on final pathologic examination had a preoperative
diagnosis of stage I, II, or III esophageal cancer. A select
portion of these patients received combined induction che-
moradiotherapy as outlined and had a complete pathologic
response. The patients with preoperative stage I disease
had T1a lesions according to preoperative endoscopic
ultrasonography.
Given the 10-year period, there might be additional bias
in terms of the management strategy over time and the de-
velopment and refinement of the various MIE techniques
during the earlier parts of our study. The percentage of
MIEs increased in the second half of the study, and, as ex-
pected, the duration of follow-up for the MIE arm was
shorter. The MIE cohort might have disproportionately
benefited from any improvements in the postoperative man-
agement techniques that tend to occur with time. Any favor-
able results in the MIE group must be viewed through that
prism. However, both open and minimally invasive proce-
dures continue to be performed concurrently at our institu-
tion; thus, the bias might not be as great. This potential bias
was further countered because postoperative management
strategies specific to each approach (OE vs MIE) have
changed little over time.
Admittedly, becoming facile with all 3 MIE techniques
can be challenging. As our experience with MIE has grown,
we have modified our technique to minimize the specific
complications encountered. The IL MIE is now performed
with a side-to-side completely stapled intrathoracic anasto-
mosis to lessen the stricture rate.13 To minimize instances of
chyle leak, we routinely ligate the thoracic duct in all pro-
cedures. To protect against possible future hernia formation,
the stomach is anchored to the diaphragm during minimally
invasive THE.
Without a prospective trial, we caution against using this
or other retrospective studies to justify a paradigm shift
away from OE as the standard of care for esophageal tu-
mors.14,19 However, from our results, we can conclude
that for early-stage esophageal cancer, a tailored minimally
invasive technique can be offered to patients that maintainsThe Journal of Thoracic and Caroncologic equivalence, including identical-to-improved
lymph node dissection, with no differences in short- or
long-term survival, and can be adopted by a single
institution.References
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